Press Releases for ENZN

Press Releases
Enzon Reports 2nd Quarter 2009 Results
CORRECTING and REPLACING Enzon to Present at BMO Focus on Healthcare Conference
Enzon to Release Second Quarter 2009 Earnings on Tuesday, August 4, 2009; Conference Call and Webcast to Follow
Enzon to Present at BMO Focus on Healthcare Conference
DellaCamera Comments on Recent Replacement of Jeffrey H. Buchalter as Chairman of Enzon and Addition of New Independent Director to Enzon’s Board
Enzon Enhances Governance with the Addition of a New Non-Executive Chairman and New Independent Director
DellaCamera Advised That Enzon Has Set July 24, 2009 as Record Date for Consent Solicitation
DellaCamera Makes Formal Request for Enzon to Set Record Date for Consent Solicitation
Enzon Commences Phase II Trial of PEG-SN38
DellaCamera Reports on Town Hall Meeting for Enzon Shareholders and Provides Update on Consent Solicitation Process
DellaCamera to Host Town Hall Meeting on June 10, 2009 for Enzon Shareholders and Other Interested Parties
Enzon Presents Clinical Data from HIF-1 Alpha Antagonist Study at ASCO
Enzon Stockholders Approve Company Proposals at 2009 Annual Meeting
UCB’s Cimzia® Approved in the U.S. for Adult Patients Suffering from Moderate to Severe Rheumatoid Arthritis
DellaCamera Provides Update on Court Developments Relating to Its Consent Solicitation to Remove CEO of Enzon
Enzon Reports Strong 1st Quarter 2009 Results
Enzon Reaches Phase II Dose for PEG-SN38
Enzon to Release First Quarter 2009 Earnings on Thursday, May 7, 2009; Conference Call and Webcast to Follow
DellaCamera Comments on Delaware Lawsuit
Enzon’s Board of Directors Reaffirms Support of Its Chairman and CEO
Enzon Continues to Improve Its Capital Structure
Significant Shareholder Seeks to Remove Enzon's CEO and President Jeffrey H. Buchalter
Significant Shareholder Seeks to Remove Enzon’s CEO and President Jeffrey H. Buchalter
Enzon Reveals New LNA Targets
Enzon Treats Patients with Survivin Antagonist
Enzon to Present at 29th Annual Cowen and Company Healthcare Conference
Enzon Reports 2008 Results
Significant Enzon Shareholder Hopeful That Management Will Provide Additional Information to the Investment Community
Enzon to Release Fourth Quarter 2008 Earnings on Thursday, February 19, 2009; Conference Call and Webcast to Follow
Significant Shareholder Calls upon Enzon to Immediately Add Two Candidates to the Board of Directors
Enzon Announces IND Acceptance for Its Survivin Antagonist
Enzon Discontinues Further Development of rhMBL
Enzon to Present at 11th Annual BIO CEO & Investor Conference
Enzon Nominates Two New Candidates for Its Board of Directors
Enzon Concludes Tender Offer for a Portion of Its Debt
Enzon Pharmaceuticals Extends Tender Offer for a Portion of Its Debt
Enzon Pharmaceuticals Commences Tender Offer for a Portion of Its Debt
Enzon to Purchase a Portion of Its Outstanding Debt
Enzon Discontinues Its Plan to Spin-off Its Biotechnology Business
Enzon Reports Solid Third Quarter 2008 Results
Technologies, Markets and the Competitive Environment of Drug Delivery Using Nanotechnologies Explored - Oct 31 2008 11:56PM
Technologies, Markets and the Competitive Environment of Drug Delivery Using Nanotechnologies Explored - Oct 31 2008 6:56AM
Enzon to Release Third Quarter 2008 Earnings on Wednesday, November 5, 2008; Conference Call and Webcast to Follow
Enzon's HIF-1 Alpha Antagonist Shows Antitumor Activity
Enzon Presents New Data on Its LNA Programs
Enzon to Present Data at EORTC-NCI-AACR
DellaCamera Sends Letter to Enzon Board of Directors
Enzon's New Oncaspar-IV(TM) Receives Orphan Drug Status in The EU
Enzon Pharmaceuticals Announces Intention to Explore Strategic Alternatives for Specialty Pharmaceuticals Business
Enzon Reports Solid Second Quarter 2008 Results
Enzon Files for Spin-off of Biotech Business
Enzon to Release Second Quarter 2008 Earnings on Wednesday, August 6, 2008; Conference Call and Webcast to Follow
Enzon Eliminates Its Remaining 2008 Debt
Jack Geltosky, Ph.D. Joins Enzon's Board of Directors
Enzon Stockholders Approve Company Proposals at 2008 Annual Meeting
Shareholder Demands Enzon Explore All Strategic Alternatives for Commercial Operations - May 27 2008 12:58AM
Enzon Announces Clinical Data from PEG-SN38 and rhMBL Studies at ASCO - May 27 2008 12:58AM
Enzon Reports Strong First Quarter 2008 Results - Jun 1 2008 9:09PM
Enzon Pharmaceuticals, Inc. Announces Plan to Spin-off Biotechnology Business - Jun 1 2008 9:09PM
Enzon to Release First Quarter 2008 Earnings on Wednesday, May 7, 2008
Cimzia(R), Utilizing Enzon's Pegylation Technology, Approved in the U.S.
Enzon to Present Preclinical Data On HIF-1alpha antagonist at AACR